MX2015015680A - Sustancia activa para tratar sarcopenia. - Google Patents

Sustancia activa para tratar sarcopenia.

Info

Publication number
MX2015015680A
MX2015015680A MX2015015680A MX2015015680A MX2015015680A MX 2015015680 A MX2015015680 A MX 2015015680A MX 2015015680 A MX2015015680 A MX 2015015680A MX 2015015680 A MX2015015680 A MX 2015015680A MX 2015015680 A MX2015015680 A MX 2015015680A
Authority
MX
Mexico
Prior art keywords
active substance
treating sarcopenia
muscle mass
mass
muscle
Prior art date
Application number
MX2015015680A
Other languages
English (en)
Other versions
MX369238B (es
Inventor
Stephan Hausmanns
Steffen Oesser
Hans-Ulrich Frech
Hans-Chrispoth Kneféli
Original Assignee
Gelita Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50588721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015015680(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gelita Ag filed Critical Gelita Ag
Publication of MX2015015680A publication Critical patent/MX2015015680A/es
Publication of MX369238B publication Critical patent/MX369238B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con un hidrolizado de colágeno como sustancia activa para tratar sarcopenia, como sustancia adiva contra la pérdida degenerativa de masa muscular y para mejorar la potencia muscular, como sustancia activa para reducir la pérdida de masa muscular relacionada con la edad, y como sustancia activa para estimular la conversión de masa de grasa corporal en masa muscular; la invención además se relaciona con un método para tratar sarcopenia, que comprende la administración oral repetida de un hidrolizado de colágeno a un paciente.
MX2015015680A 2013-05-13 2014-04-29 Hidrolizado de colágeno para usarse en el tratamiento de sarcopenia. MX369238B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102013104897.8A DE102013104897A1 (de) 2013-05-13 2013-05-13 Wirkstoff zur Behandlung von Sarkopenie
PCT/EP2014/058673 WO2014183989A1 (de) 2013-05-13 2014-04-29 Wirkstoff zur behandlung von sarkopenie

Publications (2)

Publication Number Publication Date
MX2015015680A true MX2015015680A (es) 2016-03-15
MX369238B MX369238B (es) 2019-11-01

Family

ID=50588721

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015680A MX369238B (es) 2013-05-13 2014-04-29 Hidrolizado de colágeno para usarse en el tratamiento de sarcopenia.

Country Status (15)

Country Link
US (2) US20160051618A1 (es)
EP (1) EP2996710B1 (es)
CN (1) CN105209059B (es)
AU (1) AU2014267613B2 (es)
BR (1) BR112015028249A2 (es)
CA (1) CA2928222C (es)
CL (2) CL2015003326A1 (es)
DE (1) DE102013104897A1 (es)
DK (1) DK2996710T3 (es)
ES (1) ES2857652T3 (es)
MX (1) MX369238B (es)
PL (1) PL2996710T3 (es)
PT (1) PT2996710T (es)
RU (1) RU2679802C2 (es)
WO (1) WO2014183989A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013104897A1 (de) 2013-05-13 2014-11-13 Gelita Ag Wirkstoff zur Behandlung von Sarkopenie
DE102018104590A1 (de) * 2018-02-28 2019-08-29 Gelita Ag Nutrazeutische oder pharmazeutische Zusammensetzung
US11998654B2 (en) 2018-07-12 2024-06-04 Bard Shannon Limited Securing implants and medical devices
MX2021014268A (es) * 2021-11-19 2022-02-16 Univ Mexico Nac Autonoma Proteina optimizada que comprende los aminoacidos esenciales para la nutricion humana.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU648140B2 (en) * 1991-02-01 1994-04-14 Virtual Drug Development, Inc. Reverse antimicrobial peptides and antimicrobial compositions
US6476005B1 (en) * 1998-03-24 2002-11-05 George D. Petito Oral and injectable nutritional composition
US6107460A (en) * 1999-03-01 2000-08-22 The Board Of Regents Of The University Of Oklahoma Antimicrobial peptides and methods of use thereof
US8211477B2 (en) * 2007-10-17 2012-07-03 Biova, L.L.C. Solubilized protein composition obtained from eggshell membrane
DE102009030351A1 (de) * 2009-06-22 2010-12-23 Gelita Ag Zusammensetzung zur Behandlung von degenerativen Gelenkerkrankungen
TWI526161B (zh) * 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
DE102010060564A1 (de) * 2010-11-15 2012-05-16 Gelita Ag Verwendung von Kollagenhydrolysat zur Verbesserung der Gesundheit der menschlichen Haut, Haare und/oder Nägel
US10869843B2 (en) * 2010-11-23 2020-12-22 Chemi Nutra Method for increasing muscle mass and strength
DE102011000997A1 (de) * 2011-03-01 2012-09-06 Gelita Ag Zusammensetzung für Ernährungszwecke
DK2699249T3 (en) * 2011-04-19 2017-01-09 Bioiberica cartilage Product
US20130065823A1 (en) * 2011-09-14 2013-03-14 Sergio Ammirata Supplement for Strengthening the Muscles of a Human
JP6222663B2 (ja) 2012-08-24 2017-11-01 国立大学法人徳島大学 筋委縮抑制剤
DE102012110612A1 (de) 2012-11-06 2014-05-08 Gelita Ag Kollagenhydrolysat und dessen Verwendung
US20140296137A1 (en) * 2013-04-01 2014-10-02 Los Alamos National Security, Llc Methods and compositions for controlling rotifers
DE102013104897A1 (de) 2013-05-13 2014-11-13 Gelita Ag Wirkstoff zur Behandlung von Sarkopenie

Also Published As

Publication number Publication date
EP2996710B1 (de) 2021-03-03
ES2857652T3 (es) 2021-09-29
EP2996710A1 (de) 2016-03-23
BR112015028249A2 (pt) 2017-07-25
CA2928222C (en) 2021-02-16
CL2018003346A1 (es) 2019-02-01
CN105209059A (zh) 2015-12-30
RU2015153242A (ru) 2017-06-19
US20190151399A1 (en) 2019-05-23
RU2679802C2 (ru) 2019-02-13
AU2014267613A1 (en) 2015-11-26
RU2015153242A3 (es) 2018-03-01
AU2014267613B2 (en) 2017-06-15
DK2996710T3 (da) 2021-03-29
CA2928222A1 (en) 2014-11-20
WO2014183989A1 (de) 2014-11-20
CN105209059B (zh) 2021-11-02
PT2996710T (pt) 2021-03-26
DE102013104897A1 (de) 2014-11-13
CL2015003326A1 (es) 2016-07-15
PL2996710T3 (pl) 2021-06-28
US20160051618A1 (en) 2016-02-25
MX369238B (es) 2019-11-01

Similar Documents

Publication Publication Date Title
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
EA201490746A2 (ru) Применение прогестерона при профилактике и после острого периода для улучшения исходов, связанных с сотрясением мозга
PH12015502302B1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
PH12016500978A1 (en) Piperazine derivatives having multimodal activity against pain
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
CL2018003346A1 (es) Uso de hidrolizado de colágeno para preparar un medicamento contra la pérdida degenerativa de masa muscular (sarcopenia) y para mejorar la fuerza muscular (divisional de solicitud 3326-2015).
WO2015084883A3 (en) Compositions and methods for treating osteoarthritis
PH12017500392A1 (en) Medical treatments based on anamorelin
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
PH12014502065A1 (en) Vesicular formulations
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections
GB201317815D0 (en) Oral supplementation for the reversal of human hair canities
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2016002307A (es) Tratamiento para el cancer.
MX2016002139A (es) Composicion farmaceutica y uso del (2-cianoetil)fosfonato de dietilo.
MY174186A (en) Use of an isopropanol-containing solution to combat caliciviridae
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
EA201491629A1 (ru) Способы лечения рака с использованием липоплатина
UA91458U (uk) Спосіб корекції активності ферментів крові курчат за еймеріозної інвазії
UA136951U (uk) Спосіб і препарат для прискорення консолідації переломів кісток
LV14497A (lv) Sastāvs tahikardijas novēršanai, ārstējot sāpes sirdī

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration